Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1952 1
1954 2
1955 5
1956 3
1957 5
1958 6
1959 9
1960 5
1961 7
1962 7
1963 24
1964 21
1965 15
1966 24
1967 33
1968 25
1969 29
1970 18
1971 20
1972 29
1973 36
1974 40
1975 26
1976 28
1977 27
1978 19
1979 20
1980 19
1981 27
1982 14
1983 23
1984 14
1985 17
1986 14
1987 11
1988 10
1989 10
1990 4
1991 8
1992 17
1993 11
1994 10
1995 6
1996 19
1997 50
1998 57
1999 61
2000 45
2001 25
2002 26
2003 20
2004 10
2005 19
2006 24
2007 13
2008 12
2009 15
2010 25
2011 33
2012 47
2013 62
2014 63
2015 41
2016 49
2017 44
2018 42
2019 42
2020 44
2021 48
2022 60
2023 54
2024 38

Text availability

Article attribute

Article type

Publication date

Search Results

1,701 results

Results by year

Filters applied: . Clear all
Page 1
Drugs for Treating Obesity.
Ryan DH. Ryan DH. Handb Exp Pharmacol. 2022;274:387-414. doi: 10.1007/164_2021_560. Handb Exp Pharmacol. 2022. PMID: 34783910
Older medications approved for chronic weight management (orlistat, naltrexone/bupropion, liraglutide 3 mg and, in the USA, phentermine/topiramate) have not been widely adopted by health care providers. ...
Older medications approved for chronic weight management (orlistat, naltrexone/bupropion, liraglutide 3 mg and, in the USA, phentermine
Comprehensive Review of Current and Upcoming Anti-Obesity Drugs.
Son JW, Kim S. Son JW, et al. Diabetes Metab J. 2020 Dec;44(6):802-818. doi: 10.4093/dmj.2020.0258. Epub 2020 Dec 23. Diabetes Metab J. 2020. PMID: 33389955 Free PMC article. Review.
Currently, four drugs (orlistat, naltrexone extended-release [ER]/bupropion ER, phentermine/topiramate controlled-release, and liraglutide) can be used long-term (>12 weeks) to promote weight loss by suppressing appetite or decreasing fat absorption. ...
Currently, four drugs (orlistat, naltrexone extended-release [ER]/bupropion ER, phentermine/topiramate controlled-release, and liragl …
Synthesis of Phentermine and its Derivatives.
Upadhyaya K, Shukla S, Meena BP, Dwivedi J. Upadhyaya K, et al. Curr Org Synth. 2024;21(5):583-594. doi: 10.2174/1570179420666230530095245. Curr Org Synth. 2024. PMID: 37259208 Review.
Over a year, medication for obesity has undergone substantial changes. An amphetamine-like prescription drug called Phentermine (Adipex-P, Lomaira) is used to suppress appetite. In the last few years, Phentermine and its derivatives have attracted much attention due …
Over a year, medication for obesity has undergone substantial changes. An amphetamine-like prescription drug called Phentermine (Adip …
Obesity: Pharmacotherapy.
Powell A. Powell A. FP Essent. 2020 May;492:25-29. FP Essent. 2020. PMID: 32383845
Currently, five drugs are approved for weight management in adults: phentermine, orlistat, phentermine-topiramate, bupropion-naltrexone, and liraglutide. ...
Currently, five drugs are approved for weight management in adults: phentermine, orlistat, phentermine-topiramate, bupropion-n …
Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP).
Allison DB, Gadde KM, Garvey WT, Peterson CA, Schwiers ML, Najarian T, Tam PY, Troupin B, Day WW. Allison DB, et al. Obesity (Silver Spring). 2012 Feb;20(2):330-42. doi: 10.1038/oby.2011.330. Epub 2011 Nov 3. Obesity (Silver Spring). 2012. PMID: 22051941 Free PMC article. Clinical Trial.
A 56-week randomized controlled trial was conducted to evaluate safety and efficacy of a controlled-release combination of phentermine and topiramate (PHEN/TPM CR) for weight loss (WL) and metabolic improvements. ...
A 56-week randomized controlled trial was conducted to evaluate safety and efficacy of a controlled-release combination of phentermine
Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.
Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, Schwiers M, Day WW, Bowden CH. Garvey WT, et al. Am J Clin Nutr. 2012 Feb;95(2):297-308. doi: 10.3945/ajcn.111.024927. Epub 2011 Dec 7. Am J Clin Nutr. 2012. PMID: 22158731 Free PMC article. Clinical Trial.
BACKGROUND: Obesity is a serious chronic disease. Controlled-release phentermine/topiramate (PHEN/TPM CR), as an adjunct to lifestyle modification, has previously shown significant weight loss compared with placebo in a 56-wk study in overweight and obese subjects with 2 w …
BACKGROUND: Obesity is a serious chronic disease. Controlled-release phentermine/topiramate (PHEN/TPM CR), as an adjunct to lifestyle …
Phentermine in the Modern Era of Obesity Pharmacotherapy: Does It Still Have a Role in Treatment?
Lewis KH, Gudzune KA, Ard JD. Lewis KH, et al. Curr Obes Rep. 2024 Mar;13(1):132-140. doi: 10.1007/s13679-023-00546-9. Epub 2024 Jan 3. Curr Obes Rep. 2024. PMID: 38172485 Review.
RECENT FINDINGS: Recent research on phentermine is sparse and consists primarily of observational studies with methodologic limitations. ...There is no data to support the notion that phentermine is addictive. Although it remains the most commonly prescribed AOM in …
RECENT FINDINGS: Recent research on phentermine is sparse and consists primarily of observational studies with methodologic limitatio …
[Current State of Pharmacotherapy in Obesity].
Kim WJ. Kim WJ. Korean J Gastroenterol. 2024 Mar 25;83(3):94-101. doi: 10.4166/kjg.2024.016. Korean J Gastroenterol. 2024. PMID: 38522852 Free article. Review. Korean.
Currently, four medications are available for long-term use in Korea: Orlistat, Naltrexone/bupuropion NR, Phentermine/topiramate capsule, and Liraglutide. Recently, semaglutide and tirzepatide have been attracting attention because of their effectiveness and convenience, b …
Currently, four medications are available for long-term use in Korea: Orlistat, Naltrexone/bupuropion NR, Phentermine/topiramate caps …
Phentermine/topiramate for the treatment of obesity.
Smith SM, Meyer M, Trinkley KE. Smith SM, et al. Ann Pharmacother. 2013 Mar;47(3):340-9. doi: 10.1345/aph.1R501. Ann Pharmacother. 2013. PMID: 23482732 Review.
OBJECTIVE: To review the pharmacology, efficacy, and safety of phentermine/topiramate (PHEN/TPM) in the management of obese patients. DATA SOURCES: MEDLINE (1966-July 2012) was searched using the terms weight loss, obesity, phentermine and topiramate, phentermine
OBJECTIVE: To review the pharmacology, efficacy, and safety of phentermine/topiramate (PHEN/TPM) in the management of obese patients. …
Pharmacotherapy for obesity.
Lee PC, Dixon J. Lee PC, et al. Aust Fam Physician. 2017;46(7):472-477. Aust Fam Physician. 2017. PMID: 28697290 Free article.
1,701 results